Elsevier

Journal of Neuroimmunology

Volume 297, 15 August 2016, Pages 92-97
Journal of Neuroimmunology

Family-based association study of interleukin 10 (IL10) and interleukin 10 receptor alpha (IL10RA) functional polymorphisms in schizophrenia in Polish population

https://doi.org/10.1016/j.jneuroim.2016.05.010Get rights and content

Highlights

  • Association analysis of functional polymorphisms of IL10 and IL10RA in schizophrenia

  • Family-based study on 146 trios using transmission disequilibrium test

  • Lack of association for IL10: rs1800872, rs1800871, rs1800896, rs1800890, rs6676671

  • Lack of association with schizophrenia for IL10RA: rs3135932, rs2229113

  • Haplotype analysis—no association with schizophrenia in Polish population

Abstract

Schizophrenia is a heterogeneous disorder and its etiology remains incompletely elucidated. Among possible causes, immunological factors have been implicated in its pathogenesis and course. Interleukin-10 (IL10) and it's receptor IL10RA may play an important role for immunological aspects in etiologies of major psychiatric disorders including schizophrenia. The aim of this study was to perform a transmission disequilibrium test (TDT) on a group of 146 schizophrenia trios from the Polish population. Functional polymorphisms from IL10 (rs1800872, rs1800871, rs1800896, rs1800890, and rs6676671) and IL10RA (rs3135932 and rs2229113) genes were analyzed. A lack of association with schizophrenia was detected for IL10 and IL10RA single polymorphisms and haplotypes

Introduction

Schizophrenia is a heterogeneous disorder and its etiology remains incompletely elucidated. Among the possible causes, immunological factors have been implicated in its pathogenesis and course. The inflammatory system may trigger or modulate the course of schizophrenia through complex mechanisms influencing neurodevelopment, neuroplasticity and neurotransmission (Na et al., 2014). A concept of the relationship between psychiatric symptoms and immunological abnormalities was formed over a hundred years ago (Drzyzga et al., 2006). In the last three decades a range of cytokine alterations has been found in acute and chronic schizophrenia patients (Altamura et al., 2013, Benros et al., 2012, Drexhage et al., 2010, Ganguli et al., 1994, Gibney and Drexhage, 2013, Mansur et al., 2012). Cytokines are supposed to play a critical role in infectious and inflammatory processes, mediating the cross-talk between the brain and the immune system (Mansur et al., 2012).

Interleukin 10 (IL10) is a cytokine mainly produced by immune cells and exhibits diverse activities in various organs. It has been detected in the brain and human glia cells are considered a major source of IL10 (Chabot et al., 1999). IL10 may play an important role for immunological aspects in etiologies of major psychiatric disorders including schizophrenia (Eskdale et al., 1997, Jun et al., 2003). IL10 is biologically active as a homodimer and activates the IL10RA and IL10RB receptor complex. IL10 helps to downregulate the inflammatory immune response (Muller et al., 2013). IL10 suppresses the expression of other inflammatory molecules and is an extremely important anti-inflammatory and immunosuppressive cytokine in humans (Brocker et al., 2010). IL10 activity suppresses cell-mediated immune responses by hindering T cell proliferation and by altering the activation potential of professional antigen presenting cells, such as dendritic cells and macrophages (O'Garra et al., 2008). IL10 also promotes the proliferation of B cells and thereby enhances humoral immunity (Freudenreich et al., 2010). IL10 prevents glutamate and N-methyl-d-aspartate (NMDA)-mediated cell death in vitro (Bachis et al., 2001). It also attenuates the degeneration of dopaminergic neurons (Qian et al., 2006). There is the evidence that an altered functionality of IL10 may influence the dopamine balance (Platzer et al., 2000, Shibata et al., 1997).

Increased IL10 serum levels in schizophrenia were detected (Cazzullo et al., 1998, de Witte et al., 2014, Kunz et al., 2011, Maes et al., 2002, Rothermundt et al., 1996). However, other studies on patients with schizophrenia reported decreased serum IL10 levels (Kaminska et al., 2001, Xiu et al., 2014). Also recent meta-analysis showed that blood IL10 level was significantly lower in acutely relapsed schizophrenics (Miller et al., 2011). Paranoid patients produce less IL10 than other chronic schizophrenia patients (Cazzullo et al., 1998). Another meta-analysis conducted by Potvin et al. (2008) shows no significant effect sizes in the in vitro secretion of IL10 by peripheral blood leukocytes from schizophrenia patients (Potvin et al., 2008). No differences in IL10 gene expression in peripheral blood cells were also observed in patients with schizophrenia (Freudenreich et al., 2010).

Numerous studies reported that treatment with antipsychotic drugs affects the cytokine network (Pollmacher et al., 1996). Chlorpromazine increases the release and the circulating levels of IL10 and this effect was partly associated with the protective activity of chlorpromazine against endotoxic shock (Drzyzga et al., 2006). Increases in the levels of IL10 were found in the in vitro study with chlorpromazine, haloperidol, and clozapine (Szuster-Ciesielska et al., 2004) as well as in plasma of schizophrenic patients during treatment with risperidone (Cazzullo et al., 1998) and aripiprazole (Sobis et al., 2015). Sobis et al. (2015) also observed that the improvement in psychopathological symptoms (PANSS positive, negative and total scores) after 28 days of aripiprazole treatment was closely related to a significant increase in the IL10 level (Sobis et al., 2015). However, de Witte et al. (2014) found that the levels of IL10 were decreased in 32 antipsychotic-naïve first-episode schizophrenia patients who had been followed up and treated for 6 weeks with atypical antipsychotics, and noticed that the changes in IL10 levels were significantly correlated with the improvements in negative, general and total symptom scores in PANSS (de Witte et al., 2014). Maes et al. (2002) reported an increased serum level of IL10 in patients with schizophrenia resistant to treatment who received clozapine (Maes et al., 2002). Another study of IL10 plasma level in schizophrenic patients showed no significant changes compared to those of baseline after antipsychotic treatment with olanzapine, risperidone and quetiapine (Pae et al., 2006).

Heritability estimates of the interleukin levels based on twin studies range from 50 to 75% for IL10 (Tekola Ayele et al., 2012). The IL10 gene is located on chromosome region 1q31–32 (Eskdale et al., 1997), a locus that has been reported to be linked to genetic susceptibility to schizophrenia (Gurling et al., 2001, Hovatta et al., 1999).

The human IL10 receptor (IL10R) is a heterotetramer composed of two receptor chains (IL10RA and IL10RB). The IL10RA chain plays a dominant role in mediating high-affinity ligand binding and signal transduction, whereas the IL10RB subunit is thought to be required for signaling only (Moore et al., 2001).

Section snippets

Material and methods

The study was performed on a group of 146 trios (patients diagnosed with schizophrenia and their healthy parents). There were 65 males (mean age 24.3; SD 6.7) and 81 females (mean age 26.9; SD 6.8) in the patients' group. Mean age of onset of the first psychotic episode was 22.9 years. In 21 patients family history of schizophrenia and in 42 patients family history of other psychiatric disorders have been confirmed. Mean age of parents at the recruitment time was: fathers 55.9 (SD 8.44), mothers

Theory/calculation

A total of 7 polymorphisms of the IL10 and IL10RA genes, each selected on the basis of molecular evidence for functionality, were investigated in this study. The SNPs investigated in the IL10 gene (− 592C/A, rs1800872; − 819C/T, rs1800871; − 1082A/G, rs1800896; − 3575T/A, rs1800890; and − 6752A/T, rs6676671) have been characterized as promoter region regulatory variants (Misener et al., 2008, Yilmaz et al., 2005). Two single nucleotide polymorphisms (SNPs) of the IL10 receptor 1 (IL10RA) caused a

Results

All polymorphisms did not deviate from the Hardy–Weinberg equilibrium.

No association of the polymorphisms from IL10 (rs1800872, rs1800871, rs1800896, rs1800890, and rs6676671) and IL10RA (rs3135932 and rs2229113) genes with schizophrenia were found. Results are presented in Table 1.

All five studied SNPs within IL10 were in strong linkage disequilibrium (Fig. 1). We also performed haplotype analysis of haplotype block in the IL10 gene (consisting of − 592C/A, rs1800872; − 819C/T, rs1800871; − 

Discussion

The mutations in IL10 gene promoter sequences might alter IL10 protein production in vitro (Kube et al., 2001). Three biallelic polymorphisms (− 1082G/A, − 819C/T, and − 592C/A) may have a functional effect on IL10 transcription activation and cytokine production (Turner et al., 1997) and have been found to be strongly connected with schizophrenia in the Caucasian population (Paul-Samojedny et al., 2010).

A modest increase in frequency of the − 592A allele and − 592A/A genotype in the schizophrenic

Conclusions

Our results do not support the theory that polymorphisms of IL10 and IL10RA genes are involved in the pathogenesis of schizophrenia, but they should be interpreted very carefully. Although the present study showed a negative association of IL10 and IL10RA gene polymorphisms with schizophrenia, it does not mean an exclusion of IL10 and IL10RA genes for the etiologic factors in this disease. Probably an increase in the number of patients studied would not alter our conclusion, but negative

Role of the funding source

This study was supported by the grant of the Polish Ministry of Science and High Education number NN 402407339. The funding source had no involvement in study design, in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.

References (67)

  • M. Maes et al.

    Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor

    Schizophr. Res.

    (2002)
  • B.J. Miller et al.

    Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects

    Biol. Psychiatry

    (2011)
  • N. Muller et al.

    Anti-inflammatory treatment in schizophrenia

    Prog. Neuro-Psychopharmacol. Biol. Psychiatry

    (2013)
  • K.S. Na et al.

    The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia

    Prog. Neuro-Psychopharmacol. Biol. Psychiatry

    (2014)
  • C.U. Pae et al.

    Antipsychotic treatment may alter T-helper (TH) 2 arm cytokines

    Int. Immunopharmacol.

    (2006)
  • C. Pickard et al.

    Interleukin-10 (IL10) promoter polymorphisms and multiple sclerosis

    J. Neuroimmunol.

    (1999)
  • C. Platzer et al.

    Catecholamines trigger IL-10 release in acute systemic stress reaction by direct stimulation of its promoter/enhancer activity in monocytic cells

    J. Neuroimmunol.

    (2000)
  • S. Potvin et al.

    Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review

    Biol. Psychiatry

    (2008)
  • M. Rothermundt et al.

    Production of cytokines in acute schizophrenic psychosis

    Biol. Psychiatry

    (1996)
  • J. Sobis et al.

    Therapeutic effect of aripiprazole in chronic schizophrenia is accompanied by anti-inflammatory activity

    Pharmacol. Rep.

    (2015)
  • L. de Witte et al.

    Cytokine alterations in first-episode schizophrenia patients before and after antipsychotic treatment

    Schizophr. Res.

    (2014)
  • M.H. Xiu et al.

    Decreased interleukin-10 serum levels in first-episode drug-naive schizophrenia: relationship to psychopathology

    Schizophr. Res.

    (2014)
  • V. Yilmaz et al.

    IL-12 and IL-10 polymorphisms and their effects on cytokine production

    Cytokine

    (2005)
  • L. Yu et al.

    An association between polymorphisms of the interleukin-10 gene promoter and schizophrenia in the Chinese population

    Schizophr. Res.

    (2004)
  • S.M. Al-Asmary et al.

    Genetic variants of interleukin-10 gene promoter are associated with schizophrenia in Saudi patients: a case-control study

    N. Am. J. Med. Sci.

    (2014)
  • B. Almoguera et al.

    ATA homozigosity in the IL-10 gene promoter is a risk factor for schizophrenia in Spanish females: a case control study

    BMC Med. Genet.

    (2011)
  • O.A. Andreassen et al.

    Genetic pleiotropy between multiple sclerosis and schizophrenia but not bipolar disorder: differential involvement of immune-related gene loci

    Mol. Psychiatry

    (2015)
  • A. Bachis et al.

    Interleukin-10 prevents glutamate-mediated cerebellar granule cell death by blocking caspase-3-like activity

    J. Neurosci.

    (2001)
  • M.E. Benros et al.

    Autoimmune diseases and infections as risk factors for schizophrenia

    Ann. N. Y. Acad. Sci.

    (2012)
  • L. Bocchio Chiavetto et al.

    Association between promoter polymorphic haplotypes of interleukin-10 gene and schizophrenia

    Biol. Psychiatry

    (2002)
  • C. Brocker et al.

    Evolutionary divergence and functions of the human interleukin (IL) gene family

    Hum. Genomics

    (2010)
  • S. Chabot et al.

    Mechanisms of IL-10 production in human microglia-T cell interaction

    J. Immunol.

    (1999)
  • E. Crawley et al.

    Polymorphic haplotypes of the interleukin-10 5′ flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis

    Arthritis Rheum.

    (1999)
  • View full text